Abstracts tagged "Sjogren’s syndrome"

Abstract Number: 2543 • 2014 ACR/ARHP Annual Meeting
Anti-Ro/SSA Positive Incomplete Sjögren’s Syndrome
R. Hal Scofield¹, Anne Igoe², Donald U Stone³, Lida Radfar⁴, Kimberly S. Hefner⁵, David M. Lewis⁶, Stephen Young⁶, Judy Harris⁷, Kiely Grundahl⁷, Biji T. Kurien⁸, Jacen Maier-Moore⁹, Kristi A. Koelsch¹⁰, James Chodosh¹¹, Nelson L. Rhodus¹², Raj Gopalakrishnan¹³, Barbara M. Segal¹⁴, A. Darise Farris¹⁵, Courtney G. Montgomery¹⁶, Christopher J. Lessard¹⁷, Kathy L. Sivils¹⁸ and Astrid Rasmussen⁷, ¹US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ²Metro Health, Cleveland, OH, ³Dean McGee Eye Institute, Oklahoma City, OK, ⁴College of Dentristry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Hefner Eye Care and Optical Center, Oklahoma City, OK, ⁶College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁷Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸U.S. Department of Veterans Affairs Medical Center, Oklahoma City, OK, ⁹Dept. of Clinical Laboratory Science, University of Texas at El Paso, El Paso, TX, ¹⁰Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Okalahoma City, OK, ¹¹Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, ¹²University of Minnesota, Minneapolis, MN, ¹³Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, ¹⁴Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹⁵Arthritis and Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁷825 N.E. 13th St., Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Sjögren’s syndrome (SS) is a systemic disease characterized by dry eyes and mouth resulting from immune mediated damage and dysfunction of the lacrimal and…
Abstract Number: 526 • 2014 ACR/ARHP Annual Meeting
A Descriptive and Comparative Study of the Transcriptome from Salivary Exosomes of Sjögren’s Syndrome Patients Using RNA-Seq
Alessia Gallo¹, Mayank Tandon², Shyh-Ing Jang³, Ana Paola Cotrim⁴ and Ilias Alevizos⁵, ¹NIH, Bethesda, MD, ²Sjogren's Clinic, NIDCR, Bethesda, MD, ³Molecular Physiology and Therapeutics Branch, NIDCR, Bethesda, MD, ⁴NIDCR, NIH, Bethesda, MD, ⁵Sjogren's Clinic, NIDCR/ NIH #10 1N110, Bethesda, MD
Background/Purpose Saliva is a biofluid secreted by the salivary glands (SGs) that is critical for the health of the oral cavity. In Sjögren’s Syndrome (SS),…
Abstract Number: 2932 • 2014 ACR/ARHP Annual Meeting
Increased Risk of Deep Vein Thrombosis and Pulmonary Embolism in Sjögren’s Syndrome: A General Population-Based Cohort Study
Marko Yurkovich¹, Hyon K. Choi², Eric C. Sayre³, Kamran Shojania⁴ and J. Antonio Avina-Zubieta⁵, ¹Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Boston University School of Medicine, Boston, MA, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada
Background/Purpose: There is limited data available on the risk of deep venous thrombosis (DVT) and pulmonary embolism (PE) in Sjögren's Syndrome (SjS). We estimated the…
Abstract Number: 2541 • 2014 ACR/ARHP Annual Meeting
Autoantibodies in Pediatric Sjogren’s Patients
Lakshmanan Suresh¹, Minako Tomiita², Akira Hoshioka³, Long Shen⁴, Kishore Malyavantham⁵ and Julian Ambrus⁶, ¹60 Pineview Drive, State University of New York/Buffalo, Buffalo, NY, ²Department of Allergy and Rheumatology, Chiba Children’s Hospital, Chiba, Japan, ³Department of Allergy and Rheumatology,, Chiba Children’s Hospital,, Chiba, Japan, ⁴Department of Medicine, SUNY at Buffalo, Buffalo, NY, ⁵Research and Development, IMMCO Diagnostics Inc ., Amherst, NY, ⁶100 High St., University Of Buffalo, Buffalo, NY
Background/Purpose Sjogren’s syndrome (SS) is a common autoimmune disease involving the salivary and lacrimal glands along with various other organs. It is generally seen in…
Abstract Number: 525 • 2014 ACR/ARHP Annual Meeting
The Genetic Basis of Sjögren’s Syndrome (SS) Clinical Manifestations from Genome-Wide Association Analysis of Subphenotype Extremes in an International Cohort
Lindsey A. Criswell¹, Kimberly E. Taylor^2,3, Quenna Wong⁴, David M. Levine⁴, Caitlin McHugh⁴, Cathy Laurie⁴, Kimberly Doheny⁵, Mi Y. Lam⁶, Alan N. Baer⁷, Stephen Challacombe⁸, Yi Dong⁹, Hector Lanfranchi¹⁰, Morten Schiødt¹¹, M. Srinivasan¹², Susumu Sugai¹³, Hisanori Umehara¹⁴, Frederick B. Vivino¹⁵, Zhao Yan¹⁶, Stephen Shiboski¹⁷, Troy Daniels¹⁸, John S. Greenspan⁶, Caroline H. Shiboski⁶ and Sjögren's Syndrome Collaborative Clinical Alliance (SICCA)¹⁹, ¹Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ²Medicine, University of California San Francisco, San Francisco, CA, ³University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ⁴University of Washington, Biostatistics, Seattle, WA, ⁵Center for Inherited Disease Research, Baltimore, MD, ⁶Orofacial Sciences, University of California San Francisco, San Francisco, CA, ⁷Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Kings College London, London, United Kingdom, ⁹Dept of Rheumatology, Peking Univ Med Coll Hospital, East City Beijing, China, ¹⁰University of Buenos Aires, Buenos Aires, Argentina, ¹¹Oral and Maxillofacial Surgery, Rigshospitalet, Copenhagen, Denmark, ¹²Aravind Eye Hospital, Madurai, India, ¹³Kanazawa Medical University, Ishikawa, Japan, ¹⁴Internal Medicine, Division of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan, ¹⁵Medicine, Penn Presbyt Med Ctr, Philadelphia, PA, ¹⁶Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China, ¹⁷Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, ¹⁸Orofacial Sciences, Box 0422, University of California San Francisco, San Francisco, CA, ¹⁹University of California San Francisco, San Francisco, CA
Background/Purpose Our goal is to define the contribution of genetic factors to two hallmark manifestations of SS, keratoconjunctivitis sicca (KCS) and focal lymphocytic sialadenitis (FLS),…
Abstract Number: 2933 • 2014 ACR/ARHP Annual Meeting
Metabolic Syndrome, Adipocytokines and Inflammation in Sjögren’s Syndrome
Kristopherson Lustosa Augusto¹, Eloisa Bonfá², Rosa M. R. Pereira¹, Cleonice Bueno³, Vilma S. T. Viana⁴ and Sandra G. Pasoto⁵, ¹Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ²Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil, ³Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁴Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
Background/Purpose Systemic inflammation has been linked to increased frequency of metabolic syndrome (MetS) in autoimmune diseases. However, there are no studies concerning the frequency of…
Abstract Number: 2540 • 2014 ACR/ARHP Annual Meeting
Sjö™, an Advanced Diagnostic Panel for Detection of Sjögren’s Syndrome Autoantibodies
Mark Jasek¹, Kishore Malyavantham², Lakshmanan Suresh³, Julian Ambrus⁴ and Dennis Pardo⁵, ¹Medical and Scientific Affairs, Nicox Inc, Fort Worth, TX, ²Office of Science & Technology, IMMCO Diagnostics Inc., Amherst, NY, ³60 Pineview Drive, State University of New York/Buffalo, Buffalo, NY, ⁴Division of Allergy, Immunology and Rheumatology, Department of Medicine, State University of New York at Buffalo, Buffalo, NY, ⁵Professional Affairs, Nicox Inc, Fort Worth, TX
Background/Purpose Sjögren’s syndrome (SS) is a complex autoimmune disease involving the salivary and lacrimal glands along with various systemic manifestations. It is a difficult disease to…
Abstract Number: 524 • 2014 ACR/ARHP Annual Meeting
Distinct Patterns of DNA Methylation in Labial Salivary Gland Tissue Based on Sjögren’s Syndrome Disease Status
Michael Cole¹, Xiaorong Shao¹, Diana Quach², Hong L. Quach², Lisa F. Barcellos² and Lindsey A. Criswell³, ¹Genetic Epidemiology and Genomics Lab, Division of Epidemiology, University of California, Berkeley, Berkeley, CA, ²Epidemiology, University of California, Berkeley, Berkeley, CA, ³Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA
Background/Purpose Sjögren’s Syndrome (SS, OMIM #270150) is a chronic, multi-system autoimmune disease characterized by progressive destruction of the exocrine glands, with subsequent mucosal and conjunctival…
Abstract Number: 2934 • 2014 ACR/ARHP Annual Meeting
Abatacept reduces Circulating Effector Memory T-Helper Cells in Patients with Primary Sjögren’s Syndrome
Gwenny Verstappen¹, Wayel H. Abdulahad², Petra M. Meiners³, Suzanne Arends⁴, Silvia Beijer-Liefers⁵, Arjan Vissink³, Frans G.M. Kroese⁴ and Hendrika Bootsma⁴, ¹Rheumatology & Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁴Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁵University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background/Purpose In an open-label proof of concept study, Abatacept has been identified as an effective and safe treatment modality in primary Sjögren’s syndrome (pSS). Abatacept…
Abstract Number: 2533 • 2014 ACR/ARHP Annual Meeting
Utility of the American-European Consensus Group and American College of Rheumatology Classification Criteria for Sjögren’s Syndrome in Patients with Systemic Autoimmune Diseases in the Clinical Setting
Gabriela Hernandez-Molina¹, Carmen Ávila-Casado², Carlos Núñez-Álvarez³, Carlos Hernández-Hernández⁴, Maria Luisa Calderillo⁴, Martha Marroquín⁴, Claudia Recillas-Gispert⁵, Juanita Romero-Díaz³ and Jorge Sánchez-Guerrero⁶, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ²Pathology, University Health Network, Toronto Canada., Toronto, ON, Canada, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁴Dental Service, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁵Ophtalmology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁶Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: To evaluate the feasibility and performance of the AECG and ACR Classification Criteria for Sjögren’s syndrome (SS) in patients with systemic autoimmune diseases. Methods:…
Abstract Number: 523 • 2014 ACR/ARHP Annual Meeting
Serum CXCL4 Is Increased in Patients with Primary Sjögren’s Syndrome and Is Associated with Features of Microvascular Impairment
Rosaria Irace¹, Antonella Riccardi¹, Daniela Iacono¹, Luciana Pellecchia¹, Lucia Vicedomini¹, Gabriele Valentini² and Serena Vettori¹, ¹Internal and Experimental Medicine, Second University of Naples, Naples, Italy, ²Internal and Experimental Medicine, Second University of Naples, Napoli, Italy
Background/Purpose CXCL4 is a pleiotropic antiangiogenic and immunomodulatory chemokine. We aimed to investigate CXCL4 serum levels in primary Sjögren’s syndrome (pSS) and looked for associations…
Abstract Number: 2806 • 2014 ACR/ARHP Annual Meeting
Characteristic Phenotype of Peripheral Blood Lymphocytes in Patients with IgG4-Related Disease, Comparing to Primary Sjögren Syndrome and Healthy Controls
Shintaro Hirata, Shingo Nakayamada, Satoshi Kubo, Maiko Yoshikawa, Naoki Yunoue, Kazuhisa Nakano, Kunihiro Yamaoka, Kazuyoshi Saito and Yoshiya Tanaka, The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose : IgG4-related disease (IgG4-RD) is a systemic disease that is characterized by the infiltration of IgG4-positive plasma cells and T cells into various organs.…
Abstract Number: 2531 • 2014 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolism in Patients with Sjogren’s Syndrome: A Systematic Review and Meta-Analysis
Patompong Ungprasert¹, Charat Thongprayoon², Karn Wijarnpreecha³, Wisit Cheungpasitporn², Praveen Ratanasrimetha⁴ and Promporn Suksaranjit⁵, ¹Department of Internal medicine, Bassett medical center, Cooperstown, NY, ²Department of Medicine, Mayo clinic, Rochester, MN, ³Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁴Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, ⁵Department of Cardiology, University of Utah School of Medicine, Salt Lake City, UT
Risk of Venous Thromboembolism in Patients with Sjogren's Syndrome: A Systematic Review and Meta-analysisBackground/Purpose: Venous thromboembolism (VTE) is a common medical problem with a significant…
Abstract Number: 521 • 2014 ACR/ARHP Annual Meeting
CXCL13 Serum Levels Is Associated with Lymphoma, High B Cells Markers and Diseases activity in Primary Sjögren ’s Syndrome Patients
Gaetane Nocturne¹, Olivier Fogel², Philippe Dieude³, Jean Jacques Dubost⁴, Anne-Laure Fauchais⁵, Vincent Goeb⁶, Eric Hachulla⁷, Claire Larroche⁸, Véronique Le Guern⁹, Jacques Morel¹⁰, Aleth Perdriger¹¹, Xavier Puéchal¹², Stephanie Rist Bouillon¹³, Valerie Devauchelle¹⁴, Damien Sène¹⁵, O Vittecoq¹⁶, Corinne Miceli-Richard¹⁷, Jacques Gottenberg¹⁸ and Xavier Mariette¹⁹, ¹INSERM U1012, Paris sud university, Le Kremlin Bicetre, France, ²INSERM U1012, Paris sud university, Le Kremlin Bicêtre, France, ³Rhumatologie, Hopital Bichat Claude Bernard, Paris, France, ⁴Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, ⁵Department of Internal Medicine A, Dupuytren Hospital, Limoges University Hospital, Limoges, France, ⁶Rhumatology Department, University Hospital, AMIENS, France, ⁷Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ⁸Internal Medicine, Avicenne Hospital,, Assistance Publique des Hôpitaux de Paris,, Bobigny, France, ⁹Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹⁰Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ¹¹Rhumatologie, Rennes, France, ¹²National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹³Rhumatologie, Hopital La Source, La Source, France, ¹⁴Rheumatology, Brest university medical school, EA 2216, Lab Ex, INSERM, IGO,UBO and CHU de la Cavale Blanche,, Brest, France, ¹⁵Hopital Lariboisière, service de Médecine Interne, Paris, France, ¹⁶Rouen University Hospital & Inserm U905, Rouen, France, ¹⁷Rheumatology Department, Université Paris-Sud 11, Bicêtre Hospital,, Kremlin Bicêtre, France, ¹⁸Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹⁹rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France
Background/Purpose: Development of non-Hodgkin lymphoma (NHL) is one of the most severe complications associated with pSS. It affects 5-10% of the patients. Definition of predictive…
Abstract Number: 2725 • 2014 ACR/ARHP Annual Meeting
Enhanced Expression of CCL25 to Facilitate Increased Numbers of CCR9-Expressing Tfh-like Cells in Salivary Glands of Primary Sjögren’s Syndrome Patients
S.L.M. Blokland^1,2, M.R. Hillen^1,2, A.a. Kruize², A. Kislat³, S. Meller³, B. Homey³, G.M. Smithson⁴, J. Zalevsky⁵, T.R.D.J. Radstake² and J.a.G. van Roon², ¹Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Department of Dermatology, University of Düsseldorf, Medical Faculty, Düsseldorf, Germany, ⁴Takeda Pharmaceuticals International, Chicago, IL, ⁵Takeda California, San Diego, CA
Background/Purpose In primary Sjögren’s syndrome (pSS) B cell activation and autoantibody secretion are hallmark immunopathological features. Specific lymphoid organization (including germinal centers) is associated with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].